Liposomal sustained-release compositions containing a therapeutic drug and use thereof
AssigneesTlc Biopharmaceuticals, Inc., Taiwan Liposome Co., Ltd.
InventorsYun-Long Tseng, Hsin-Yi Chiu
Life of this patent
Estimating the term…
Abstract
Provided is a liposomal sustained-release composition comprising a therapeutic agent and one or more lipids. The therapeutic agent and total lipids are present in the liposomal sustained-released composition at a predetermined ratio. The liposomal sustained-release composition achieves a desired therapeutic effect while avoiding undesired side effects. The therapeutic agent is stably entrapped in the liposomes of the composition and sustainably released therefrom. This liposomal formulation for the therapeutic agent demonstrates an improved release profile.
Claims17
A liposomal sustained-release composition, comprising:
- a liposome and a pharmaceutically effective amount of an imidazoquinoline compound,
- wherein the liposome comprises a lipid bilayer comprising one or more lipids, and an aqueous interior encompassed by the lipid bilayer and entrapping the imidazoquinoline compound,
- wherein the imidazoquinoline compound is selected from the group consisting of resiquimod, imiquimod, gardiquimod, CL075, and SM-011, and
- wherein the imidazoquinoline compound and total lipids are present in the liposomal sustained-release composition at a predetermined ratio ranging from 0.0001 mol/mol to 0.15 mol/mol.
Dependencies are inferred from the claim text.